New Drug Applications

Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab – Complete Response Letter

4 years ago
by David Miller
1,026 Views
Written by David Miller

Brussels (Belgium), 13th May 2022 – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA)…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]